Founded in 2020, MediLink has since built a differentiated proprietary tumor microenviroment activable LINker-payload (TMALIN) ADC technology platform.

It can generate homogeneous ADC, and further improve the therapeutic window in treatment of solid tumors. We focus clinical drug development on unmet medical needs and will continuously expand into new disease areas to serve the global patients.